Assenagon Asset Management S.A. Decreases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Assenagon Asset Management S.A. lessened its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 62.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 385,420 shares of the company's stock after selling 639,205 shares during the period. Assenagon Asset Management S.A. owned about 0.10% of GoodRx worth $2,675,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of GDRX. Beacon Capital Management LLC purchased a new stake in shares of GoodRx in the 1st quarter worth approximately $28,000. nVerses Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter worth approximately $33,000. Plato Investment Management Ltd purchased a new stake in shares of GoodRx in the 2nd quarter worth approximately $43,000. Dark Forest Capital Management LP bought a new position in shares of GoodRx during the 2nd quarter worth approximately $86,000. Finally, EntryPoint Capital LLC raised its stake in shares of GoodRx by 165.2% during the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company's stock worth $132,000 after acquiring an additional 11,548 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.17% of the company's stock.

GoodRx Price Performance

Shares of NASDAQ GDRX traded down $0.20 during mid-day trading on Thursday, reaching $6.18. The company's stock had a trading volume of 342,694 shares, compared to its average volume of 1,369,806. The stock has a 50-day moving average of $7.22 and a two-hundred day moving average of $7.55. The stock has a market capitalization of $2.35 billion, a P/E ratio of -48.08, a P/E/G ratio of 4.17 and a beta of 1.37. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx Holdings, Inc. has a 1-year low of $4.14 and a 1-year high of $9.26.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business had revenue of $200.60 million during the quarter, compared to analyst estimates of $200.47 million. During the same quarter last year, the company earned $0.02 earnings per share. GoodRx's quarterly revenue was up 5.7% on a year-over-year basis. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Raymond James upgraded shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price objective for the company in a research note on Friday, August 9th. Citigroup reduced their price objective on shares of GoodRx from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Finally, UBS Group cut their price target on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $9.36.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.